Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
P501-AS15 vaccine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| P501-AS15 vaccine | BIOLOGICAL | - |
Inclusion criteria: * Male, * Aged between 18 and 75 years, inclusive, * Histologically or cytologically proven adenocarcinoma of the prostate before the initiation of therapy of the primary tumor, * Radical prostatectomy before progression of disease by rising PSA was established, * Primary tumor ...
P501-AS15 vaccine is an investigational immunotherapy studied as a first-line treatment for hormone-sensitive prostate cancer in patients who show rising prostate-specific antigen (PSA) levels. It is being developed by GSK plc for prostate cancer and related neoplasms. It has not been approved for any indication.
P501-AS15 vaccine is being developed by GSK plc, which trades under the ticker GSK. The company is responsible for the clinical program evaluating the vaccine in prostate cancer.
P501-AS15 vaccine is in Phase 1 clinical development. It is an investigational product and has not received FDA approval. The Phase 1 trial has been completed.
P501-AS15 vaccine has been evaluated in one completed Phase 1 trial, NCT00148928, titled "Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA." The trial enrolled 25 male patients aged 18 years and older in Belgium and France.
P501-AS15 vaccine is a vaccine-based immunotherapy designed to stimulate an immune response against prostate cancer. It is being studied in patients with hormone-sensitive prostate cancer who have rising PSA levels after initial treatment.